Sun Ruirui, Gou Yang, Pan Long, He Qiang, Zhou Yin, Luo Yi, Wu Chenrui, Zhao Yaowu, Fu Zixuan, Huang Ping
Department of Hepatobiliary Surgery, The First Affiliated Hospital of Chongqing Medical University, Chongqing, 400000, China.
Department of Radiography, The First Affiliated Hospital of Chongqing Medical University, Chongqing, 400000, China.
Cell Oncol (Dordr). 2024 Dec;47(6):2265-2276. doi: 10.1007/s13402-024-01015-8. Epub 2024 Nov 25.
We aimed to explore the curative effects of hepatic arterial infusion chemotherapy (HAIC) combined with Tislelizumab and Lenvatinib on unresectable hepatocellular carcinoma (HCC).
From September 2021 to September 2023, 42 patients with unresectable HCC who were treated in the First Affiliated Hospital of Chongqing Medical University were enrolled in this retrospective single-arm study. They received HAIC combined with Tislelizumab and lenvatinib. Baseline characteristics, laboratory indicators before and after treatment, and imaging findings were collected from medical records. The primary endpoint was objective response rate (ORR), and the secondary endpoints included disease control rate (DCR), overall survival (OS), progression-free survival (PFS), and safety indicators.
A total of 199 HAIC treatments were performed, with a median of 5.5 times (3.75-6.0 times). Based on the mRECIST and RECIST1.1 criterion, the ORR was 71.4% and 57.1%, the DCR was 92.9% and 92.9%. Up to the follow-up date of October 1, 2024, the median PFS was 14.0 months (95% CI, 11.6-16.4 months), and the median OS was 26.0 months.The incidence of any grade of adverse events was 97.6%. The most commonly reported treatment-related grade 3-4 adverse events included thrombocytopenia (28.6%), elevated total bilirubin (19%), and abdominal pain (16.7%). There was no treatment-related death.
For unresectable HCC, HAIC combined with tirelizumab and lenvatinib has good anti-tumor efficacy and acceptable adverse reactions.
我们旨在探讨肝动脉灌注化疗（HAIC）联合替雷利珠单抗和仑伐替尼治疗不可切除肝细胞癌（HCC）的疗效。
2021年9月至2023年9月，在重庆医科大学附属第一医院接受治疗的42例不可切除HCC患者纳入了这项回顾性单臂研究。他们接受了HAIC联合替雷利珠单抗和仑伐替尼治疗。从病历中收集基线特征、治疗前后的实验室指标以及影像学检查结果。主要终点为客观缓解率（ORR），次要终点包括疾病控制率（DCR）、总生存期（OS）、无进展生存期（PFS）和安全性指标。
共进行了199次HAIC治疗，中位数为5.5次（3.75 - 6.0次）。根据mRECIST和RECIST1.1标准，ORR分别为71.4%和57.1%，DCR分别为92.9%和92.9%。截至2024年10月1日的随访日期，中位PFS为14.0个月（95%CI，11.6 - 16.4个月），中位OS为26.0个月。任何级别的不良事件发生率为97.6%。最常报告的3 - 4级治疗相关不良事件包括血小板减少（28.6%）、总胆红素升高（19%）和腹痛（16.7%）。无治疗相关死亡。
对于不可切除的HCC，HAIC联合替雷利珠单抗和仑伐替尼具有良好的抗肿瘤疗效和可接受的不良反应。
